AI Article Synopsis
- The study examines anti-factor Xa activity (AXA) levels in patients with non-valvular atrial fibrillation (NVAF) undergoing edoxaban treatment.
- The measurement of AXA values revealed no significant differences in trough and peak levels between patients taking 60 mg and 30 mg doses of edoxaban.
- The findings suggest that adhering to the recommended dosing is crucial to ensure the medication's effectiveness.
Article Abstract
Background: The distribution of anti-factor Xa activity (AXA) values in non-valvular atrial fibrillation (NVAF) patients on edoxaban therapy has not been fully elucidated.
Methods and results: The steady-state trough and peak AXA values were measured in 66 NVAF patients. The trough AXA value did not differ significantly between the 60-mg and the 30-mg OD groups (0.17±0.13 IU/ml vs. 0.12±0.11 IU/ml, respectively; P=0.17). Similarly, the peak AXA value did not differ significantly between the 2 groups (1.45±0.81 IU/ml vs. 1.25±0.48 IU/ml, respectively; P=0.26).
Conclusions: Recommended dosing should be followed for sufficient efficacy of edoxaban. (Circ J 2016; 80: 745-747).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1253/circj.CJ-15-1281 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!